7+3

Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

Retrieved on: 
Monday, September 9, 2019
Chemical compounds, Organic compounds, Amides, Piperazines, Lactams, Cyclacel, Breakthrough therapy, Genentech, Sapacitabine, 7+3, Olaparib, Chemotherapy regimen

We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study, said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.

Key Points: 
  • We are excited to report that the first patient has been treated with oral CYC065 in part 3 of our Phase 1 study, said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.
  • We look forward to reporting data from Part 2 and 3 of this study in 2020.
  • The DNA damage response program is evaluating an oral combination regimen of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS.
  • An IST is evaluating an oral combination regimen of sapacitabine and olaparib in patients with BRCA mutant breast cancer.

Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference   

Retrieved on: 
Wednesday, September 4, 2019
Chemical compounds, Organic compounds, Breakthrough therapy, Genentech, Cyclacel, Venetoclax, Sapacitabine, 7+3

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology.

Key Points: 
  • Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage response biology.
  • The transcriptional regulation program is evaluating CYC065 in combination with venetoclax in patients with relapsed or refractory CLL and AML/MDS.
  • The DNA damage response program is evaluating an oral combination regimen of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS.
  • Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Retrieved on: 
Wednesday, September 4, 2019
RTT, Acute myeloid leukemia, Phosphoinositide 3-kinase inhibitor, AML, Leukemia, 7+3, Clinical medicine

Jean-Pierre Latere, Chief Operating Officer of Celyad, said,The dosing of the first patient with CYAD-01 manufactured with the OptimAb process marks another important milestone for our company.

Key Points: 
  • Jean-Pierre Latere, Chief Operating Officer of Celyad, said,The dosing of the first patient with CYAD-01 manufactured with the OptimAb process marks another important milestone for our company.
  • We look forward to reporting preliminary data from patients enrolled in the DEPLETHINK trial treated with CYAD-01 produced with the OptimAb process by the end of the year.
  • The OptimAb manufacturing process utilizes a shortened cell culture and incorporates a selective PI3K inhibitor.
  • Preclinical data demonstrate that CYAD-01 produced using the OptimAb manufacturing process drives improved anti-tumor activity in an aggressive acute myeloid leukemia (AML) model compared to CYAD-01 produced with the previous mAb manufacturing process.

Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Retrieved on: 
Monday, August 26, 2019
Cancer treatments, Nucleosides, Chemical compounds, Lactams, Organic compounds, Decitabine, Janssen Pharmaceutica, Otsuka Pharmaceutical, Triazines, Myelodysplastic syndrome, 7+3, Vadastuximab talirine

The key change in the amended Phase 2 study is the inclusion of patients with high risk myelodysplastic syndrome (MDS) and refractory/relapsed AML patients.

Key Points: 
  • The key change in the amended Phase 2 study is the inclusion of patients with high risk myelodysplastic syndrome (MDS) and refractory/relapsed AML patients.
  • The restructured Phase 2 clinical trial has two cohorts of patients.
  • The amended Phase 2 study will continue evaluating the safety of prexigebersen in combination with decitabine in both cohorts of patients at a dose of 60 mg/m2 in combination with decitabine.
  • The study will include a total of six evaluable patients for a safety assessment of prexigebersen and decitabine.

Global Infusion Pump Software Market Analysis, Trends & Industry Forecasts 2016-2018 & 2019-2027

Retrieved on: 
Monday, August 19, 2019
Medicine, Clinical medicine, Health, Dosage forms, Infusion pump, MINE, Chemotherapy, 7+3

DUBLIN, Aug. 19, 2019 /PRNewswire/ -- The "Global Infusion Pump Software Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 19, 2019 /PRNewswire/ -- The "Global Infusion Pump Software Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Some of the prominent trends that the market is witnessing include high growth in emerging countries, rising adoption of specialty infusion systems, and recent technological developments in infusion pump software.
  • By the Indication, the market is segmented into the enteral infusion, pain & anesthesia management, general infusion, chemotherapy, insulin infusion, and other indications.
  • Based on the Type, the market is fragmented into interoperability software, dose error reduction software (DERS), clinical workflow software, and other types.

Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib

Retrieved on: 
Tuesday, August 6, 2019
Chemical compounds, Health, Organic compounds, Breakthrough therapy, Tyrosine kinase inhibitors, Acrylamides, Ibrutinib, Piperidines, Pyrazolopyrimidines, Clinical trial, Dose-ranging study, 7+3

This CR appears to be durable, and has been confirmed after 6, 9 and 11 months of cirmtuzumab plus ibrutinib treatment.

Key Points: 
  • This CR appears to be durable, and has been confirmed after 6, 9 and 11 months of cirmtuzumab plus ibrutinib treatment.
  • The CIRLL Study (CIRM-0001) is a Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib in patients with CLL or MCL.
  • Part 1 of the study was a Phase 1 dose-finding portion designed to determine the Phase 2 dose, or recommended dosing regimen (RDR).
  • Part 3 of the study, which is now open for enrollment, is a Phase 2 study in which approximately 90 patients with CLL will be randomized to receive either ibrutinib alone or ibrutinib plus cirmtuzumab, with a primary endpoint of complete response rate.

UChicago Medicine Launches Virtual Consultation Services Through PinnacleCare for Second Opinions

Retrieved on: 
Tuesday, July 30, 2019
Technology, Mobile, Wireless, Software, Practice Management, Internet, General Health, Health, Acute myeloid leukemia, Cancer, 7+3

PinnacleCare, the premier health advisory firm, today announced that University of Chicago Medicine, an academic health system and a leading center of excellence, has launched remote second opinion services through the PinnacleCare VirtualConnect platform.

Key Points: 
  • PinnacleCare, the premier health advisory firm, today announced that University of Chicago Medicine, an academic health system and a leading center of excellence, has launched remote second opinion services through the PinnacleCare VirtualConnect platform.
  • This valuable tool eliminates geographic barriers to expert medical care around the globe enabling patients to access medical reviews and remote second opinions without the need for travel or medical transport.
  • Access through remote second opinion services provides a seamless way for families to create a remote dialogue with top providers they may have otherwise been unable to reach.
  • PinnacleCares VirtualConnect platform enabled UChicago Medicine to work with a patient from Indiana who was diagnosed with acute myeloid leukemia (AML).

Biotech Brief: Acute Myeloid Leukemia Market to Reach $1.5 Billion Dollars by 2024

Retrieved on: 
Thursday, July 18, 2019
Acute myeloid leukemia, RTT, Cancer, 7+3, Leukemia, Minimally differentiated acute myeloblastic leukemia, Extramedullary

A report from Mordor Intelligence states: "The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%.

Key Points: 
  • A report from Mordor Intelligence states: "The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%.
  • Among them, the number of new cases of acute myeloid leukemia (AML) will be around21,450, from which most of the population will be adults.
  • This statistic shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impactthe growth of the AML market in the United States.
  • 3 patients were treated at dose level of 150 mg/m2 with no drug-related adverse events, including no signs of cardiotoxicity.

Biotech Brief: Acute Myeloid Leukemia Market to Reach $1.5 Billion Dollars by 2024

Retrieved on: 
Thursday, July 18, 2019
Acute myeloid leukemia, RTT, Cancer, 7+3, Leukemia, Minimally differentiated acute myeloblastic leukemia, Extramedullary

A report from Mordor Intelligence states: "The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%.

Key Points: 
  • A report from Mordor Intelligence states: "The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%.
  • Among them, the number of new cases of acute myeloid leukemia (AML) will be around21,450, from which most of the population will be adults.
  • This statistic shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impactthe growth of the AML market in the United States.
  • 3 patients were treated at dose level of 150 mg/m2 with no drug-related adverse events, including no signs of cardiotoxicity.

Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort

Retrieved on: 
Thursday, July 18, 2019
Cancer treatments, Cancer, Chemical compounds, Acute myeloid leukemia, 7+3, Piperidines, Antibody-drug conjugates, Pyrimidines, Gilteritinib, Camidanlumab tesirine

"Recruitment in Poland continues to move rapidly," commented Walter Klemp, Moleculin's Chairman and CEO.

Key Points: 
  • "Recruitment in Poland continues to move rapidly," commented Walter Klemp, Moleculin's Chairman and CEO.
  • "And, moving beyond the 150 mg/m2 dosing level is quite significant, as the prior developer of Annamycin was unable to dose beyond this level.
  • The Company is studying Annamycin in both the US and Poland in open label, single arm clinical trials to assess the safety and efficacy of Annamycin for the treatment of adults with relapsed or refractory acute myeloid leukemia.
  • Now that 3 patients have completed the safety evaluation period of the second cohort in Poland, the third cohort will begin there at a dose level of 180 mg/m2.